SX-682

Research use only, not for human use.

SX-682 is a potent, selective and orally bioavailable inhibitor of CXCR1/2 ,has the potential to treat castration-resistant prostate cancer.

SX-682 is a potent, selective and orally bioavailable inhibitor of CXCR1/2 ,has the potential to treat castration-resistant prostate cancer.SX-682 significantly inhibited trafficking of PMN-MDSCs without altering CXCR2 ligand expression. Trafficking of CXCR1+ macrophages was unaltered, possibly due to coexpression of CSF1R. Reduced PMN-MDSC tumor infiltration correlated with enhanced accumulation of endogenous or adoptively transferred T cells. Accordingly, tumor growth inhibition or the rate of established tumor rejection following programed death-axis (PD-axis) immune checkpoint blockade or adoptive cell transfer of engineered T cells was enhanced in combination with SX-682.

——

Animal Model:C57BL/6NTac-Tyrtm1Arte?female mice Dosage:50 mg/kg Administration:Orally; twice a day on a Monday through Friday Result:Has Meager to moderate effects on CRPC progression.

——

Autophagy

CXCR

CXCR1|CXCR2

Cancer

Melanoma Stage IiiMelanoma Stage Iv

1648843-04-2

467.2

C19H14BF4N3O4S

>98% (HPLC)

DMSO:250 mg/mL (535.10 mM; Need ultrasonic)

OB(O)c1ccc(OC(F)(F)F)cc1CSc1ncc(cn1)C(=O)Nc1ccc(F)cc1

——

(-20℃)

With Ice Pack

≥ 2 years